Physician profile
Matthew D Johnson
NPI 1013199124
$2,490.05
in general payments reported to CMS, 2019-2025
34 companies · $19.91 in 2025
The $19.91 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $103 · 2021: $503 · 2022: $377 · 2023: $469 · 2024: $291 · 2025: $19.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $269.48 | 2019-2024 | Belbuca |
| Abbvie INC. | $233.37 | 2021-2025 | |
| Horizon Therapeutics Plc | $201.46 | 2019-2021 | |
| Pfizer INC. | $161.09 | 2019-2023 | |
| Daiichi Sankyo INC. | $143.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.55 | 2023-2024 | Relistor |
| Biohaven Pharmaceuticals, INC. | $123.29 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $118.28 | 2022 | |
| Electronic Waveform Lab, INC. | $91.86 | 2020-2024 | |
| Redhill Biopharma INC. | $79.67 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $73.18 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $71.57 | 2019-2023 | |
| Grt US Holding, INC. | $70.63 | 2021-2022 | |
| Abbott Laboratories | $67.95 | 2023-2024 | Proclaim, Eterna |
| Ibsa Pharma INC. | $59.18 | 2021-2023 | Tirosint, Licart |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $56.88 | 2021-2023 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $56.37 | 2019-2021 | |
| Nevro Corp. | $54.25 | 2022-2023 | Senza |
| Relievant Medsystems, INC. | $47.54 | 2023 | Intracept |
| Novartis Pharmaceuticals Corporation | $41.63 | 2019 | |
| Bioventus LLC | $34.23 | 2021 | |
| Si-Bone, INC. | $33.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.11 | 2019 | |
| Almatica Pharma LLC | $32.67 | 2021-2023 | Gralise |
| Pacira Pharmaceuticals Incorporated | $27.04 | 2022 | |
| Biodelivery Sciences International, INC. | $26.07 | 2019 | |
| Vertiflex, INC. | $20.79 | 2019 | |
| Allergan, INC. | $20.00 | 2021 | |
| Fidia Pharma USA INC. | $19.39 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.07 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.79 | 2022 | |
| Lilly USA, LLC | $17.35 | 2020 | |
| Zyla Life Sciences, INC. | $12.86 | 2019 | |
| Hikma Pharmaceuticals USA | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.